This review describes the currently available targetable nanocarriers, focusing particularly on one of the newest nanocarriers, lipid nanocapsules. All of the strategies that are likely to be exploited by lipid nanocapsules to bypass blood-central nervous system barriers, including the most recent ...
research team, the proposed NK-92/5.28.z cell therapy has shown a promising synergistic effect when combined with PD-1 checkpoint inhibition in murine models.181,182 This combina- torial approach enhanced the cytotoxic CAR-NK effect and enabled the treatment of gliomas refractory to the mono- ...
The latter is one of the newest diagnostic tools being used to define those patients that may respond best to treatment. All of these proteins identified in my research as being affected by mAR activation are considered of extreme importance in GBM pathology. This coupled with the results ...
JW CreaGene, a subsidiary of JW Shinyak, said Thursday that it has started recruiting patients participating in phase 1/2 clinical trials for CreaVax-BC, a glioblastoma treatment. CreaVax-BC is a therapy that induces Cytotoxic T Lymphocyte (CTL) by injecting glioblastoma-specific cancer antigen...